NASDAQ:SIGY

Sigyn Therapeutics Stock Forecast, Price & News

$0.58
0.00 (0.00 %)
(As of 09/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.58
$0.58
50-Day Range
$0.52
$1.00
52-Week Range
$0.30
$3.50
Volume450 shs
Average Volume3,035 shs
Market Capitalization$21.27 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.85
30 days | 90 days | 365 days | Advanced Chart
Receive SIGY News and Ratings via Email

Sign-up to receive the latest news and ratings for Sigyn Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Sigyn Therapeutics logo

About Sigyn Therapeutics

Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company, which focuses on the treatment of life-threatening inflammatory conditions that are precipitated by cytokine storm syndrome. The company was founded by James A. Joyce and Craig P. Roberts on December 15, 2014 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.33 out of 5 stars

Medical Sector

1302nd out of 1,351 stocks

Surgical & Medical Instruments Industry

122nd out of 123 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Sigyn Therapeutics (NASDAQ:SIGY) Frequently Asked Questions

What stocks does MarketBeat like better than Sigyn Therapeutics?

Wall Street analysts have given Sigyn Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sigyn Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Sigyn Therapeutics' earnings last quarter?

Sigyn Therapeutics, Inc. (NASDAQ:SIGY) released its earnings results on Monday, August, 16th. The company reported ($0.02) earnings per share (EPS) for the quarter.
View Sigyn Therapeutics' earnings history
.

Who are Sigyn Therapeutics' key executives?

Sigyn Therapeutics' management team includes the following people:
  • James A. Joyce, Chairman, Chief Executive & Financial Officer
  • Craig P. Roberts, Chief Technology Officer
  • Eric Lynam, Head-Clinical Affairs

What is Sigyn Therapeutics' stock symbol?

Sigyn Therapeutics trades on the NASDAQ under the ticker symbol "SIGY."

How do I buy shares of Sigyn Therapeutics?

Shares of SIGY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sigyn Therapeutics' stock price today?

One share of SIGY stock can currently be purchased for approximately $0.58.

How much money does Sigyn Therapeutics make?

Sigyn Therapeutics has a market capitalization of $21.27 million and generates $30,000.00 in revenue each year.

How many employees does Sigyn Therapeutics have?

Sigyn Therapeutics employs 2 workers across the globe.

What is Sigyn Therapeutics' official website?

The official website for Sigyn Therapeutics is www.sigyntherapeutics.com.

Where are Sigyn Therapeutics' headquarters?

Sigyn Therapeutics is headquartered at 8880 Rio San Diego Ste. 800, San Diego CA, 92108.

How can I contact Sigyn Therapeutics?

Sigyn Therapeutics' mailing address is 8880 Rio San Diego Ste. 800, San Diego CA, 92108. The company can be reached via phone at (213) 457-3772.


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.